GLP-1 drugs may be able to sustain their weight loss effects even months after discontinuing the popular obesity drugs, ...

Many patients using highly effective GLP-1 drugs like Wegovy may not regain lost weight quickly when they stop treatment, ...

CAMBRIDGE, Mass., March 23, 2021 /PRNewswire/ -- nference, the AI-driven health technology company, today announced publication in EClinicalMedicine of study "Pre-existing conditions are associated ...

CAMBRIDGE, Mass., May 4, 2021 /PRNewswire/ -- nference, the AI-driven health technology company, today announced that it has been named as a finalist in the Fast Company World Changing Ideas Awards in ...

nference’s federated AI platform is being leveraged to provide access to the deepest clinical data to generate insights and better inform decision-making CAMBRIDGE, Mass.--(BUSINESS WIRE)--nference, a ...

CAMBRIDGE, Mass. & LEXINGTON, Mass., March 18, 2025--(BUSINESS WIRE)--Valo Health, Inc. ("Valo"), a biotechnology company focused on transforming the drug discovery and development process using human ...

CAMBRIDGE, Mass., April 17, 2025 /PRNewswire/ -- nference, a company dedicated to transforming healthcare by making biomedical data computable, today announced a collaboration with BeiGene, Ltd, a ...

EHR data company nference on Wednesday launched its real-world evidence generation platform and expanded its existing partnership with the Mayo Clinic. The platform, dubbed nSights, collects ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--nference, a science-first software company transforming healthcare data for research and discovery, and Emory Healthcare, the most comprehensive academic health ...

Nference has raised $60 million. The Mayo Clinic-backed series B round positions nference to forge ahead with its effort to capture and analyze health data, including unstructured information, to help ...